slc5a8 Antibody

What is SLC5A8 and why is it significant in research applications?

SLC5A8 is a Na+-coupled high-affinity transporter for monocarboxylates, including short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate. It functions as an electrogenic transporter with a Na+:monocarboxylate stoichiometry of 2:1 . The protein is approximately 67 kDa and is encoded by a gene that may also be known as AIT, SMCT, SMCT1, sodium-coupled monocarboxylate transporter 1, and apical iodide transporter .

Research significance:

• Tumor suppressor function: SLC5A8 is frequently silenced in various cancers through DNA methylation

• Metabolite transport: Critical for SCFA uptake in intestinal epithelium and other tissues

• Immune regulation: Plays a role in mucosal immune tolerance via butyrate transport

• Drug transport: Mediates uptake of certain therapeutic compounds including dichloroacetate

What applications can SLC5A8 antibodies be used for in laboratory research?

Based on validated applications from multiple suppliers, SLC5A8 antibodies can be used for:

Methodological considerations: For optimal results, antigen retrieval using TE buffer (pH 9.0) is recommended for IHC applications, though citrate buffer (pH 6.0) may be used as an alternative . For Western blot detection, the molecular weight of approximately 67 kDa should be observed .

How should I validate the specificity of an SLC5A8 antibody?

A multi-step validation approach is recommended:

• Positive control tissues: Use tissues known to express high levels of SLC5A8 such as kidney, colon, and brain tissues from human, mouse, or rat samples .

• Blocking peptide validation: Pre-incubate the antibody with the immunizing peptide before application. This should abolish specific staining, as demonstrated in rat supraoptic nucleus immunohistochemistry .

• Negative controls:

  • Omit primary antibody during incubation

  • Use tissues/cells where SLC5A8 is known to be silenced (certain cancer cell lines)

• Molecular weight verification: Confirm detection at the expected molecular weight of 67 kDa in Western blots .

• Functional validation: If possible, compare expression in cells with known SLC5A8 functional status (e.g., before and after treatment with DNA demethylating agents like 5-azacytidine in cancer cell lines) .

What are the optimal protocols for detecting SLC5A8 in different subcellular compartments?

SLC5A8 localization varies by cell type and physiological/pathological status. Notably, it demonstrates both cytoplasmic and nuclear localization in certain cancers, with nuclear translocation associated with poorer prognosis in pancreatic cancer .

Membrane/cytoplasmic detection protocol:

• For formalin-fixed paraffin-embedded (FFPE) samples, use antigen retrieval with sodium citrate (pH 6.0) at 95°C for 30 minutes or TE buffer (pH 9.0)

• Block with universal blocking serum for 30 minutes

• Incubate with primary SLC5A8 antibody at 4°C overnight

• Use biotin-labeled secondary antibody and streptavidin-peroxidase (30 minutes each)

• Develop with 3,3′-diaminobenzidine and counterstain with hematoxylin

Nuclear detection protocol:

• Follow the same basic protocol as above

• Consider using confocal microscopy for precise subcellular localization

• Use nuclear counterstain (DAPI or Hoechst)

• Quantify nuclear expression as percentage of cells with nuclear staining (≥5% is considered positive for nuclear expression)

How can I effectively study SLC5A8 expression changes in cancer models?

SLC5A8 is frequently silenced in cancer through epigenetic mechanisms. The following methodological approach can be used to study its expression:

• Baseline expression analysis:

  • Perform RT-PCR and Western blot to determine mRNA and protein expression levels

  • Use IHC on tissue microarrays to compare expression in tumor vs. adjacent non-neoplastic tissue

• Reactivation studies:

  • Treat cancer cell lines with DNA demethylating agents (5-azacytidine or 5-aza-2'-deoxycytidine)

  • Confirm reactivation by RT-PCR and Western blot

  • Evaluate functional consequences through transport assays or downstream effects

• Ectopic expression systems:

  • Use both inducible (e.g., TetOn) and constitutive expression systems

  • Verify expression by RT-PCR, Western blot, and transport activity

  • Assess effects on cell phenotype (proliferation, apoptosis, colony formation)

• Quantification approaches:

  • For IHC, use a semiquantitative scoring system combining staining intensity (0-3) and percentage of cells stained (0-3)

  • Calculate expression score as the product of intensity and percentage (range: 0-9)

What are the critical considerations for using SLC5A8 antibodies in co-localization studies?

When performing co-localization studies with SLC5A8 and other proteins:

• Antibody compatibility:

  • Ensure primary antibodies are raised in different host species

  • For double immunofluorescence, select antibodies with minimal cross-reactivity

• Epitope accessibility:

  • Optimize antigen retrieval conditions for both targets

  • Test different fixation protocols if working with cultured cells

• Controls to include:

  • Single staining controls for each antibody

  • Secondary antibody-only controls

  • Known co-localization controls if available

• Imaging considerations:

  • Use confocal microscopy for precise subcellular localization

  • Apply appropriate spectral separation to minimize bleed-through

  • Consider super-resolution techniques for membrane localization studies

• Quantification methods:

  • Use Pearson's or Mander's coefficients for quantitative co-localization analysis

  • Consider 3D reconstruction for spatial relationship analysis

How can I address conflicting SLC5A8 expression data in my research?

Researchers sometimes encounter contradictory results regarding SLC5A8 expression. Methodological approaches to address this include:

• Antibody validation:

  • Validate antibody specificity using multiple approaches (blocking peptide, knockout/knockdown controls)

  • Confirm with antibodies targeting different epitopes of SLC5A8

• Expression context:

  • Consider tissue-specific expression patterns

  • Evaluate expression in relation to cell differentiation status

  • Account for epigenetic regulation in different cell types/conditions

• Methodological triangulation:

  • Employ multiple detection methods (RT-PCR, Western blot, IHC, IF)

  • Assess functional activity through transport assays

  • Correlate protein expression with mRNA expression

• Biological variability assessment:

  • Increase sample size to account for biological variability

  • Stratify samples based on relevant clinical/biological parameters

  • Consider genetic/epigenetic heterogeneity of samples

What are the optimal experimental approaches for studying SLC5A8's role in transport of specific substrates?

SLC5A8 transports various monocarboxylates including SCFAs and certain drugs. To study its substrate-specific transport:

• Electrophysiological approaches:

  • Use two-microelectrode voltage-clamp technique in Xenopus oocytes expressing SLC5A8

  • Monitor inward currents upon substrate exposure in the presence/absence of Na+

• Cell-based transport assays:

  • Use SLC5A8-expressing cells vs. control cells

  • Measure substrate uptake using radiolabeled or fluorescently labeled substrates

  • Compare transport kinetics (Km, Vmax) for different substrates

• Pharmacological inhibition:

  • Use competitive inhibitors to determine substrate specificity

  • Employ Na+ substitution to confirm Na+-dependence of transport

• Structure-activity relationship studies:

  • Test structurally related compounds (e.g., dichloroacetate vs. monochloroacetate)

  • Determine minimal structural requirements for transport

• Mutagenesis approaches:

  • Generate SLC5A8 mutants affecting potential substrate binding sites

  • Assess impact on transport activity for specific substrates

How can I effectively study the epigenetic regulation of SLC5A8 in my research model?

SLC5A8 is frequently silenced by DNA methylation in cancer cells. To study this regulation:

• Methylation analysis techniques:

  • Perform bisulfite sequencing of the SLC5A8 promoter region

  • Use methylation-specific PCR (MSP) for targeted analysis

  • Consider genome-wide methylation arrays for broader context

• Demethylation studies:

  • Treat cells with 5-azacytidine or 5-aza-2'-deoxycytidine

  • Monitor SLC5A8 reactivation by RT-PCR and Western blot

  • Assess functional consequences of reactivation

• Chromatin immunoprecipitation (ChIP):

  • Analyze histone modifications at the SLC5A8 promoter

  • Investigate recruitment of DNA methyltransferases or methyl-CpG binding proteins

• Functional studies:

  • Correlate methylation status with functional outcomes

  • Assess impact of SLC5A8 reactivation on sensitivity to HDAC inhibitors or other therapeutics

• Clinical correlation:

  • Compare SLC5A8 methylation status in normal vs. tumor tissues

  • Correlate methylation with clinical outcomes or therapeutic responses

What is the recommended methodology for studying SLC5A8's role in cancer progression?

Based on current research, a comprehensive approach includes:

• Expression analysis in clinical samples:

  • Compare SLC5A8 expression in tumor vs. adjacent normal tissue using IHC

  • Correlate expression patterns with clinical outcomes

  • Assess both expression level and subcellular localization

• Functional studies in cell models:

  • Restore SLC5A8 expression in silenced cancer cell lines

  • Evaluate effects on:

    • Proliferation and colony formation

    • Apoptosis (annexin V-FITC/propidium iodide staining)

    • Sensitivity to chemotherapeutic agents

    • Metabolism (particularly related to SCFA utilization)

• Mechanistic investigations:

  • Assess impact on HDAC activity using HDAC activity assays

  • Monitor changes in expression of HDAC-regulated genes (e.g., survivin)

  • Investigate interactions with metabolic pathways

• In vivo models:

  • Generate xenograft models with SLC5A8-expressing vs. control cancer cells

  • Evaluate tumor growth, invasion, and metastasis

  • Test therapeutic interventions targeting SLC5A8-mediated pathways

How can I effectively study SLC5A8's role in intestinal health and disease?

SLC5A8 plays a crucial role in SCFA transport in the intestinal epithelium, with implications for microbiome interactions and inflammatory conditions:

• Expression analysis in intestinal tissues:

  • Map SLC5A8 expression along the intestinal tract using IHC/IF

  • Compare expression in healthy vs. diseased tissues (e.g., inflammatory bowel disease)

• Functional transport studies:

  • Use intestinal epithelial cell models expressing SLC5A8

  • Measure transport of SCFAs and other substrates

  • Assess impact of inflammatory mediators on transport function

• Microbiome interaction studies:

  • Correlate microbiome profiles with SLC5A8 expression

  • Investigate effects of specific bacterial metabolites on SLC5A8 function

  • Use gnotobiotic animal models to assess specific microbial contributions

• Dietary intervention studies:

  • Manipulate dietary fiber content to alter SCFA production

  • Monitor changes in SLC5A8 expression and function

  • Assess downstream effects on mucosal immune responses

What are the best methods for studying SLC5A8 in primary cell cultures?

Working with primary cells requires special considerations:

• Isolation protocols:

  • For intestinal epithelial cells: Use chelating agents (EDTA) followed by gentle mechanical dissociation

  • For renal epithelial cells: Consider enzymatic digestion with collagenase

  • Maintain physiological conditions during isolation to preserve transporter function

• Culture conditions optimization:

  • Use tissue-specific culture media formulations

  • Consider co-culture systems to maintain cellular polarization

  • For intestinal cells, growth on permeable supports enables access to apical and basolateral compartments

• Expression verification:

  • Confirm SLC5A8 expression by RT-PCR and Western blot

  • Verify subcellular localization by immunofluorescence

  • Monitor expression stability across passages

• Functional assessments:

  • Measure transport activity using radiolabeled or fluorescent substrates

  • Assess electrophysiological properties using Ussing chambers

  • Investigate regulatory mechanisms under physiological stimuli

What are the common technical challenges when working with SLC5A8 antibodies and how can they be addressed?

What are the critical protocol modifications needed for detecting SLC5A8 in different experimental models?

Different experimental models require specific adaptations:

Cell lines:

• Fixation: 4% paraformaldehyde for 20 minutes at room temperature

• Permeabilization: 0.1-0.2% Triton X-100 for 10 minutes

• Blocking: 5% normal serum in PBS for 30-60 minutes

• Primary antibody incubation: 1:10-1:100 dilution at 4°C overnight

• Secondary antibody: Fluorophore-conjugated, 1:200 at room temperature for 30 minutes

Tissue sections (FFPE):

• Deparaffinization: Xylene (3 × 5 minutes) followed by graded ethanol rehydration

• Antigen retrieval: TE buffer pH 9.0 or citrate buffer pH 6.0 at 95°C for 12-30 minutes

• Blocking: Universal blocking serum for 30 minutes

• Primary antibody: 1:50-1:500 dilution at 4°C overnight

• Detection: Avidin-biotin-peroxidase method or fluorophore-conjugated secondary antibodies

Frozen sections:

• Fixation: 4% paraformaldehyde in PBS

• Permeabilization: 0.2% Triton X-100 for 10 minutes

• Blocking: 5% normal serum in PBS for 30 minutes

• Antibody dilutions: Higher than for FFPE (begin with manufacturer recommendations)

• Detection: Direct fluorescence or amplification methods as needed

How can contradictory findings related to SLC5A8 localization be resolved methodologically?

When faced with contradictory localization data:

• Cross-validation with different antibodies:

  • Use antibodies targeting different epitopes of SLC5A8

  • Compare monoclonal and polyclonal antibodies for consistency

• Controlled fixation comparison:

  • Compare multiple fixation methods (formaldehyde, methanol, acetone)

  • Assess epitope accessibility under different conditions

• Subcellular fractionation:

  • Perform Western blot analysis on purified membrane, cytoplasmic, and nuclear fractions

  • Compare with immunolocalization results

• Live-cell imaging:

  • Use fluorescently tagged SLC5A8 constructs to monitor localization in living cells

  • Track dynamic changes in localization under various conditions

• Super-resolution microscopy:

  • Apply techniques like STORM or STED for precise subcellular localization

  • Resolve membrane vs. near-membrane localization

• Context consideration:

  • Account for cell/tissue type specificity

  • Consider pathological state (e.g., normal vs. cancer tissue)

  • Evaluate effect of experimental manipulations on localization

By implementing these methodological approaches, researchers can better understand the complex biology of SLC5A8 and its roles in normal physiology and disease states.